| 梁洪享,杨志勇,黄燕.精准放疗联合抗PD-1/L1治疗中晚期非小细胞肺癌患者的疗效和安全性分析.[J].中南医学科学杂志.,2025,(6):1007-1010. |
| 精准放疗联合抗PD-1/L1治疗中晚期非小细胞肺癌患者的疗效和安全性分析 |
| Efficacy and safety analysis of precise radiotherapy combined with anti-PD-1/L1 therapy in patients with advanced non-small cell lung cancer |
| 投稿时间：2024-12-16 修订日期：2025-08-26 |
| DOI：10.15972/j.cnki.43-1509/r.2025.06.016 |
| 中文关键词: 精准放疗 PD-1/L1 中晚期非小细胞肺癌 疗效 安全性 |
| 英文关键词:precise radiotherapy PD-1/L1 advanced non-small cell lung cancer efficacy safety |
| 基金项目:上海市崇明区“可持续发展科技创新行动计划”项目(CKY2021-06) |
|
| 摘要点击次数: 72 |
| 全文下载次数: 29 |
| 中文摘要: |
| 目的探讨精准放疗联合抗程序性死亡分子1(PD-1)/程序性死亡分子配体1(PD-L1)治疗中晚期非小细胞肺癌(NSCLC)患者的疗效和安全性。 方法选取80例中晚期NSCLC患者,根据治疗方法不同分为对照组40例(精准放疗)和观察组40例(精准放疗联合抗PD-1/PD-L1)。比较两组临床疗效、血清肿瘤标志物、免疫功能、炎症指标、不良反应和生存情况。 结果观察组客观缓解率高于对照组(P＜0.05)。与治疗前比较,治疗后两组CEA、CA199、CA125、CD8＋、NLR、PLR降低,CD3＋、CD4＋、CD4＋/CD8＋、Karnofsky评分升高；且观察组较对照组变化更显著(P＜0.05)。两组并发症发生率比较,差异无显著性(P＞0.05)。观察组1年生存率高于对照组(P＜0.05)。 结论精准放疗联合抗PD-1/L1治疗中晚期NSCLC患者疗效显著,并未增加不良反应,有助于改善预后。 |
| 英文摘要: |
| AimTo investigate the efficacy and safety of precise radiotherapy combined with anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy in patients with advanced non-small cell lung cancer (NSCLC). MethodsEighty patients with advanced NSCLC were selected and divided into a control group (n＝40, precise radiotherapy) and an observation group (n＝40, precise radiotherapy combined with anti-PD-1/PD-L1) according to different treatment methods. The clinical efficacy, serum tumor markers, immune function, inflammatory indicators, adverse reactions, and survival were compared between the two groups. ResultsThe objective response rate in the observation group was higher than that in the control group (P＜0.05). Compared with pre-treatment levels, CEA, CA199, CA125, CD8＋, NLR, and PLR levels decreased after treatment, while CD3＋, CD4＋, CD4＋/CD8＋ ratio, and Karnofsky score increased in both groups; these changes were more significant in the observation group compared with the control group (P＜0.05). There was no statistically significant difference in the incidence of complications between the two groups (P＞0.05). The 1-year survival rate in the observation group was higher than that in the control group (P＜0.05). ConclusionPrecise radiotherapy combined with anti-PD-1/L1 therapy is effective and safe for patients with advanced NSCLC, without increasing adverse reactions, which contributes to improved prognosis. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|